Angion Biomedica

[{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Everest Clinical Research | CTI Clinical Trial and Consulting | Clinical Accelerator","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Angion Biomedica \/ Everest Clinical Research | CTI Clinical Trial and Consulting | Clinical Accelerator","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Everest Clinical Research | CTI Clinical Trial and Consulting | Clinical Accelerator"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angion Biomedica \/ National Institute of Diabetes and Digestive and Kidney Diseases","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ National Institute of Diabetes and Digestive and Kidney Diseases"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angion Biomedica \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angion Biomedica \/ National Institute of Diabetes and Digestive and Kidney Diseases","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ National Institute of Diabetes and Digestive and Kidney Diseases"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CTI Clinical Trial and Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angion Biomedica \/ CTI Clinical Trial and Consulting","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ CTI Clinical Trial and Consulting"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CTI Clinical Trial and Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angion Biomedica \/ CTI Clinical Trial and Consulting","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ CTI Clinical Trial and Consulting"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angion Biomedica \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Angion Biomedica \/ Quotient Sciences"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Nucleus Network","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angion Biomedica \/ Nucleus Network","highestDevelopmentStatusID":"6","companyTruncated":"Angion Biomedica \/ Nucleus Network"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Angion Biomedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angion Biomedica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Elicio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Merger","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angion Biomedica \/ Angion Biomedica","highestDevelopmentStatusID":"6","companyTruncated":"Angion Biomedica \/ Angion Biomedica"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ANG-3070","moa":"ROR1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ANG-3070","moa":"ROR1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Angion Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ANG-3070","moa":"ROR1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ANG-3070","moa":"ROR1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ANG-3070","moa":"ROR1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ANG-3070","moa":"ROR1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"14-C ANG-3777","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angion Biomedica \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Angion Biomedica \/ Quotient Sciences"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ANG3070","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Angion Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Elicio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Merger","leadProduct":"ELI-002 7P","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angion Biomedica \/ Elicio Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Angion Biomedica \/ Elicio Therapeutics"}]